Lentiviral vectors for the preparation of immunotherapeutical compositions
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique
InventorsPierre Charneau, Hüseyin Firat, Véronique Zennou
Life of this patent
Estimating the term…
Loading patent…
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique
InventorsPierre Charneau, Hüseyin Firat, Véronique Zennou
Estimating the term…
The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.
An immunogenic composition comprising a replication-defective, recombinant retroviral vector comprising:
A replication-defective, recombinant lentiviral vector comprising:
Dependencies are inferred from the claim text.